{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 28 of 115', '8.2. Rationale', 'The study has primary objectives designed to evaluate the safety and effectiveness of the Arctic Front', 'Advance and Freezor MAX Cardiac CryoAblation Catheters for treatment of drug refractory symptomatic', 'persistent AF. In the United States, there are no ablation catheters approved to treat subjects with', 'persistent AF. The study will provide subjects with more options for treatment and the possibility of', 'improving their health, quality of life and a decrease in stroke risk. If successful, the STOP Persistent AF', 'study will demonstrate meaningful therapeutic benefit in this underserved population. This evaluation will', 'support an indication expansion for the treatment of recurrent, symptomatic persistent AF. The study will', 'be considered successful if it meets the primary objectives, contingent upon FDA review and approval.', '9. Product Description', '9.1. General', 'In the US, Canada and Europe, centers will utilize the commercially released Arctic Front Advance Cardiac', 'CryoAblation Catheters and Freezor MAX Cardiac CryoAblation Catheters (and future commercially released', 'generations). In Japan, the devices will be provided to the centers. Instructions for use of the devices used in', 'the study are provided in their respective manuals. Device information is provided in Table 6 and described', 'below.', 'Any changes made to these devices', 'during the investigation will be subject to IDE Modification Reporting Requirements as applicable.', 'Table 6: Device Information', 'Model', 'Geography', 'Manufacturer', 'Component', 'Number', '2AF234', 'US (investigational)', 'Arctic Front', 'Medtronic, Inc.', '2AF284', 'Japan (investigational)', 'Advance', 'CryoAblation', '2AF233', 'Catheter', 'Canada (non-investigational)', 'Medtronic, Inc.', '2AF283', 'Europe (non-investigational)', '239F3', 'US (investigational)', 'Medtronic, Inc.', '239F5', 'Japan (investigational)', 'Freezor MAX', 'CryoAblation', '209F3', 'Catheter', 'Canada (non-investigational)', '209F5', 'Medtronic, Inc.', 'Europe (non-investigational)', '990063-020', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 29 of 115', '9.1.1.', 'Arctic Front Advance Cardiac CryoAblation Catheters', 'Approved indication in the US and Japan: The Arctic Front Advance Cardiac CryoAblation Catheters are', 'indicated for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation.', 'Investigational indication in the US and Japan: The Arctic Front Advance Cardiac CryoAblation Catheters are', 'indicated for the treatment of drug refractory recurrent symptomatic paroxysmal and persistent atrial', 'fibrillation.', 'Approved indication in Europe and Canada: The Arctic Front Advance Cardiac CryoAblation Catheter is', 'indicated for the treatment of patients with atrial fibrillation.', 'The catheters are sterile, single use, minimally invasive intravascular balloon catheters specifically designed', 'for tissue cryoablation. The Arctic Front Advance Cardiac CryoAblation Catheter is used together with the', 'CryoConsole and related devices. Arctic Front Advance catheters are percutaneously advanced to the heart', 'chamber from the femoral access via a transseptal sheath in the vasculature. Once the catheter reaches the', 'left atrium, the balloon is inflated and the cooling segment creates circumferential lesions at the antrum of', 'the targeted pulmonary veins.', '9.1.2.', 'Freezor MAX Cardiac CryoAblation Catheters', 'Approved indication in the US and Japan: The Freezor MAX Cardiac CryoAblation Catheter is used as an', 'adjunctive device in the endocardial treatment of paroxysmal atrial fibrillation in conjunction with the Arctic', 'Front Advance Cardiac CryoAblation Catheter.', 'Investigational indication in the US and Japan: The Freezor MAX Cardiac CryoAblation Catheters are', 'indicated for use as an adjunctive device in the endocardial treatment of paroxysmal and persistent atrial', 'fibrillation in conjunction with the Arctic Front Advance Cardiac CryoAblation Catheter for the following', 'uses: gap cryoablation to complete electrical isolation of the pulmonary veins, cryoablation of focal trigger', 'sites and creation of ablation line between the inferior vena cava and the tricuspid valve.', 'Approved indication in Europe and Canada: The Freezor MAX Cardiac CryoAblation Catheter is intended for', 'use in treatment of cardiac arrhythmias.', 'The Freezor MAX Cardiac CryoAblation Catheter is a flexible, steerable catheter used to ablate cardiac', 'tissue. It is used together with the CryoConsole and related components. The 8mm tip of the focal Freezor', 'MAX Cryocatheter reaches cryoablation temperatures when refrigerant is injected from the CryoConsole to', 'the tip of the catheter. The catheter tip has an integrated thermocouple for temperature reading capability.', 'The catheter is introduced into the vasculature by traditional minimally invasive techniques.', '9.1.3.', 'FlexCath Advance Steerable Sheath', 'The FlexCath Advance Steerable Sheath is a percutaneous introducer fitted with a hemostasis valve to allow', 'for introduction, withdrawal and swapping of catheters and wires while providing a barrier preventing air', 'ingress into the valve and minimizing blood loss. A side-port with stopcock is integrated into the hemostasis', 'valve to allow continuous drip infusion, injection through the center lumen, flushing, aspiration, blood', 'sampling and pressure monitoring. The FlexCath Advance Steerable Sheath is intended to allow sheath', 'deflection to facilitate catheter positioning. It is supplied sterile and packaged together with a dilator.', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}